S

Supernus Pharmaceuticals
D

SUPN

35.420
USD
-0.35
(-0.98%)
Market Closed
Volume
9,429
EPS
1
Div Yield
-
P/E
33
Market Cap
1,955,866,650
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    0.140
    (0.84%)
    16.880 USD
    ALNY
    ALNY
    6.675
    (2.79%)
    245.505 USD
    A
    AVDL
    0.175
    (1.73%)
    10.305 USD
    B
    BPMC
    1.130
    (1.27%)
    90.120 USD
    ILMN
    ILMN
    2.030
    (1.52%)
    135.930 USD
    I
    IONS
    0.040
    (0.11%)
    35.630 USD
    N
    NBIX
    0.490
    (0.36%)
    135.460 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: Supernus Pharmaceuticals

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia inPD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.